MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma
Source abstract
Abstract
BACKGROUND: Recently, microRNA-133b (miR-133b) dysregulation has been shown to play a key role in several human cancers, as well as glioma. In this study, we aimed to investigate the clinical significance and prognostic value of miR-133b in glioma. METHODS: Real-time quantitative PCR was employed to measure the expression level of miR-133b in tissues. Survival analysis was carried out by using the log-rank test and Kaplan-Meier method. Prognostic factors for overall survival were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. RESULTS: The expression level of miR-133b was significantly lower in glioma tissues compared with matched non-cancerous brain tissues (p < .05). Its level was strongly correlated with Karnofsky Performance Scale score (p < .001) and WHO grade (p < .001). Kaplan-Meier survival and log-rank analysis indicated that the decreased expression of miR-133b was strongly correlated with shorter overall survival of patients with glioma (log-rank test, p = .03). CONCLUSIONS: The current investigation demonstrated that miR-133b level is useful for predicting the prognosis of patients with glioma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Glioma Diagnosis and Treatment · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong, China;
Department of Neurosurgery, Yantaishan Hospital, Yantai, Shandong, China;
Second Traumatic orthopedics, Yantaishan Hospital, Yantai, Shandong, China
References (20)
Show source-provided references
1. 10.1097/WCO.0b013e328312c3a710.1097/WCO.0b013e328312c3a7 ↗
2. 10.1007/s00401-007-0243-410.1007/s00401-007-0243-4 ↗
3. 10.1007/978-1-4614-3146-6_110.1007/978-1-4614-3146-6_1 ↗
4. 10.1155/2014/97060710.1155/2014/970607 ↗
5. 10.1016/j.cell.2005.06.03610.1016/j.cell.2005.06.036 ↗
6. 10.1160/TH11-12-083610.1160/TH11-12-0836 ↗
7. 10.18632/oncotarget.919810.18632/oncotarget.9198 ↗
8. 10.1007/s12031-014-0455-810.1007/s12031-014-0455-8 ↗
9. 10.1200/JCO.2005.04.530210.1200/JCO.2005.04.5302 ↗
10. 10.5732/cjc.013.1020710.5732/cjc.013.10207 ↗
11. 10.1038/nrc316610.1038/nrc3166 ↗
12. 10.1038/nrc199710.1038/nrc1997 ↗
13. 10.1038/nrc184010.1038/nrc1840 ↗
14. 10.1158/1078-0432.CCR-10-020710.1158/1078-0432.CCR-10-0207 ↗
15. 10.1002/cam4.77710.1002/cam4.777 ↗
16. 10.1158/1078-0432.CCR-13-158810.1158/1078-0432.CCR-13-1588 ↗
17. Akcakaya P · Int J Oncol · 2011 · 39 · 311
18. 10.4161/cbt.10.2.1218610.4161/cbt.10.2.12186 ↗
19. 10.1111/j.1742-4658.2012.08741.x10.1111/j.1742-4658.2012.08741.x ↗
20. 10.1002/ijc.2528410.1002/ijc.25284 ↗